StockData
Pfizer Inc logo

Pfizer Inc (PFE) stock

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3048% above fair value
$28.86−0.03 (-0.10%)

Close on Nov 16, 2026Market cap $164.49BP/E 38.0Yield 5.96%

Pfizer operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Pfizer's operating cash flow for the twelve months ending Jun 28, 2026 was $13.40B, down 11.8% year over year. For fiscal 2025 it was $11.70B, down 8.2% from the year before. Over ten years it grew -2.2% a year on average. The highest annual figure on record is $32.58B in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.70B-8.2%
FY2024Dec 31, 2024$12.74B+46.5%
FY2023Dec 31, 2023$8.70B-70.3%
FY2022Dec 31, 2022$29.27B-10.2%
FY2021Dec 31, 2021$32.58B+126.2%
FY2020Dec 31, 2020$14.40B+14.4%
FY2019Dec 31, 2019$12.59B-20.5%
FY2018Dec 31, 2018$15.83B-5.8%
FY2017Dec 31, 2017$16.80B+3.8%
FY2016Dec 31, 2016$16.19B+10.2%
FY2015Dec 31, 2015$14.69B-14.0%
FY2014Dec 31, 2014$17.08B-3.4%
FY2013Dec 31, 2013$17.68B+5.6%
FY2012Dec 31, 2012$16.75B-17.3%
FY2011Dec 31, 2011$20.24B+76.7%
FY2010Dec 31, 2010$11.45B-30.9%
FY2009Dec 31, 2009$16.59B-9.1%
FY2008Dec 31, 2008$18.24B+36.6%
FY2007Dec 31, 2007$13.35B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 28, 2026$835.00M–
Q1 FY2026Mar 29, 2026$2.62B+12.0%
Q4 FY2025Dec 31, 2025$5.35B-20.4%
Q3 FY2025Sep 28, 2025$4.60B-31.4%
Q2 FY2025Jun 29, 2025-$582.00M–
Q1 FY2025Mar 30, 2025$2.34B+114.2%
Q4 FY2024Dec 31, 2024$6.72B+28.3%
Q3 FY2024Sep 29, 2024$6.71B+94.3%
Q2 FY2024Jun 30, 2024-$1.78B–
Q1 FY2024Mar 31, 2024$1.09B-10.1%
Q4 FY2023Dec 31, 2023$5.24B-38.9%
Q3 FY2023Oct 1, 2023$3.46B-42.1%
Q2 FY2023Jul 2, 2023-$1.21B-114.8%
Q1 FY2023Apr 2, 2023$1.21B-81.5%
Q4 FY2022Dec 31, 2022$8.58B+45.1%
Q3 FY2022Oct 2, 2022$5.97B-44.8%
Q2 FY2022Jul 3, 2022$8.17B-27.7%
Q1 FY2022Apr 3, 2022$6.54B+44.1%
Q4 FY2021Dec 31, 2021$5.91B+5.1%
Q3 FY2021Oct 3, 2021$10.83B+418.1%
Q2 FY2021Jul 4, 2021$11.30B+217.8%
Q1 FY2021Apr 4, 2021$4.54B+44.8%
Q4 FY2020Dec 31, 2020$5.63B+49.2%
Q3 FY2020Sep 27, 2020$2.09B-53.7%
Q2 FY2020Jun 28, 2020$3.56B+36.2%
Q1 FY2020Mar 29, 2020$3.13B+84.5%
Q4 FY2019Dec 31, 2019$3.77B-20.5%
Q3 FY2019Sep 29, 2019$4.51B-14.2%
Q2 FY2019Jun 30, 2019$2.61B-32.1%
Q1 FY2019Mar 31, 2019$1.70B-14.4%
Q4 FY2018Dec 31, 2018$4.74B-33.2%
Q3 FY2018Sep 30, 2018$5.26B+7.6%
Q2 FY2018Jul 1, 2018$3.85B+18.7%
Q1 FY2018Apr 1, 2018$1.98B+25.2%
Q4 FY2017Dec 31, 2017$7.09B+17.3%
Q3 FY2017Oct 1, 2017$4.89B+3.2%
Q2 FY2017Jul 2, 2017$3.24B–
Q1 FY2017Apr 2, 2017$1.58B–
Q4 FY2016Dec 31, 2016$6.04B–
Q3 FY2016Oct 2, 2016$4.74B–

More Pfizer figures

See a number that looks wrong?